Last reviewed · How we verify
LMWH (lmwh)
Low-Molecular-Weight Heparin (LMWH) is a class of anticoagulant medications derived from unfractionated heparin and marketed by multiple manufacturers including Pfizer. The drug enhances antithrombin III activity to selectively inhibit Factor IIa and Factor Xa, preventing thrombus formation with superior pharmacokinetic predictability compared to unfractionated heparin. LMWH is FDA-approved for prevention and treatment of venous thromboembolism (DVT/PE), thromboprophylaxis in orthopedic surgery, and acute coronary syndromes, with established use in postpartum thrombosis prevention and cancer-associated thrombosis. Clinical differentiation centers on subcutaneous administration without APTT monitoring, enabling outpatient management of conditions previously requiring hospitalization. The global LMWH market represents a mature, multi-billion-dollar segment with multiple branded formulations (enoxaparin, dalteparin, tinzaparin) competing alongside direct oral anticoagulants; Pfizer's enoxaparin franchise generates substantial revenue across prevention and treatment indications. Current pipeline expansion includes novel LMWH formulations and combination therapies for specialized populations such as high-risk preeclampsia prevention and pediatric kidney transplant recipients.
At a glance
| Generic name | lmwh |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | preclinical |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMWH CI brief — competitive landscape report
- LMWH updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI